Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Journal of Geriatric Oncology|January 14, 2020
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre studyLaura Ridolfi, Francesco De Rosa, Elisabetta Petracci, et al.Breast Cancer Research and Treatment|July 10, 2026
Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world studyPalma Fedele, Alessandro Rizzo, Matteo Landriscina, et al.Cancer Immunology, Immunotherapy : CII|August 28, 2023
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE studyMelissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, et al.Nutrients|July 2, 2021
Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled TrialHarriet Johansson, Giuseppe Spadola, Giulio Tosti, et al.Frontiers in Oncology|October 12, 2020
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on SurvivalFrancesco Mannavola, Mario Mandala, Annalisa Todisco, et al.Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.The Oncologist|April 17, 2026
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone MetastasesRoberta Scafetta, Marco Donato, Carla Gullotta, et al.Pageof 6